Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007208/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of the study is to evaluate the safety and tolerability of single
ascending intravenous (IV) doses and a single subcutaneous (SC) dose of BIIB063 in healthy
volunteers. The secondary objectives of the study are to estimate the PK parameters of single
ascending IV doses of BIIB063; to estimate the PK parameters and absolute bioavailability (F)
of a single SC dose of BIIB063; and to evaluate the immunogenicity of single ascending doses
of BIIB063.
提供机构：
Vivli
创建时间：
2021-06-10
